Modern principles of anti-viral therapy of hepatitis C

Cover Page

Cite item

Full Text

Abstract

The article presents the basic principles of antiviral therapy for hepatitis C. The main objectives and importance of antiviral therapy for hepatitis C are considered. The concept of a sustained virological response is given. The necessity of determining the causal relationship between infection with the hepatitis C virus and liver damage is substantiated. The article discusses the principles of antiviral therapy using interferon and interferon-free therapy with direct-acting antiviral drugs in both patients with acute and chronic hepatitis C.

About the authors

Nikolay I. Kuznetsov

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: meri-kuz@mail.ru

DSc, Professor, Department of Infectious Diseases 

Russian Federation

Elena S. Romanova

North-Western State Medical University named after I.I. Mechnikov

Email: E.Romanova@szgmu.ru

PhD, Associate Professor of the Department of Infectious Diseases

Russian Federation

Galina Y. Startseva

North-Western State Medical University named after I.I. Mechnikov

Email: GalinaStartsevastar661@rambler.ru

PhD, Associate Professor of the Department of Infectious Diseases

Russian Federation

References

  1. Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-176. doi: 10.1016/S2468-1253(16)30181-9.
  2. Arase Y, Kobayashi M, Suzuki F, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2013;57(3):964-973. doi: 10.1002/hep.26087.
  3. Bruno S, Di Marco V, Iavarone M, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016;64(6):1217-1223. doi: 10.1016/j.jhep.2016.01.034.
  4. Kew MC. Interaction between hepatitis B and C viruses in hepatocellular carcinogenesis. J Viral Hepat. 2006;13(3):145-149. doi: 10.1111/j.1365-2893.2005.00686.x.
  5. Kew MC, Yu MC, Kedda MA, et al. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology. 1997;112(1):184-187. doi: 10.1016/S0016-5085(97)70233-6.
  6. Negro F, Forton D, Craxi A, et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149(6):1345-1360. doi: 10.1053/j.gastro.2015.08.035.
  7. Caviglia GP, Sciacca C, Abate ML, et al. Chronic hepatitis C virus infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, monoclonal gammopathy of undetermined significance, and B-cell non-Hodgkin lymphoma. J Gastroenterol Hepatol. 2015;30(4):742-747. doi: 10.1111/jgh.12837.
  8. European Association for the Study of the Liver. Electronic address: eas/office@easloffice.cu
  9. European Association for the Study of the L. J Hepatol. 2018;69(2):461-511. doi: 10.1016/j.jhep.2018.03.026.
  10. Международная ассоциация специалистов в области инфекций. Рекомендации по диагностике и лечению взрослых больных гепатитом С. – М., 2017. [Mezhdunarodnaya assotsiatsiya spetsialistov v oblasti infektsiy. Rekomendatsii po diagnostike i lecheniyu vzroslykh bol’nykh gepatitom C. Moscow; 2017. (In Russ.)]
  11. Блохина Н.П., Нурмухаметова Е.А., Русанова М.Г., и др. Эффективность и безопасность применения цепэгинтерферона альфа 2b в составе двойной (цепэгинтерферон альфа 2b и рибавирин) и тройной (симепревир, цепэгинтерферон альфа 2b и рибавирин) схемы противовирусной терапии у пациентов с хроническим гепатитом С. Опыт реальной клинической практики // Журнал инфектологии. – 2016. – Т. 8. – № 2. – С. 48–55. [Blokhina NP, Nurmukhametova EA, Rusanova MG, et al. The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir,cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice. Zhurnal infektologii. 2016;8(2):48-55. (In Russ.)]
  12. rlsnet.ru [интернет]. Инструкция к медицинскому применению препарата Софосбувир [доступ от 09.10.2018]. Доступ по ссылке https://www.rlsnet.ru/mnn_index_id_6715.htm. [Rlsnet.ru [Internet]. Instructions for medical use of the Sofosbuvir drug [cited 2018 Oct 9]. Available from: https://www.rlsnet.ru/mnn_index_id_6715.htm. (In Russ.)]
  13. rlsnet.ru [интернет]. Инструкция к медицинскому применению препарата Даклатасвир [доступ от 06.10.2018]. Доступ по ссылке https://www.rlsnet.ru/mnn_index_id_6681.htm. [Rlsnet.ru [Internet]. Instructions for medical use of the Daklatasvir drug [cited 2018 Oct 6]. Available from: https://www.rlsnet.ru/mnn_index_id_6681.htm. (In Russ.)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Kuznetsov N.I., Romanova E.S., Startseva G.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).